We found that fish oil supplementation of dyslipidemic rats decreased serum and liver triglyceride levels, reduced the progression of NAFLD, decreased the hepatic MPO activity, and increased both erythrocyte and liver SOD activities. The gene discussed is SOD1; the disease is metabolic dysfunction-associated steatotic liver disease.